{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:11Z","timestamp":1793214611612,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ajoc.2022.101634","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T19:28:12Z","timestamp":1656185292000},"page":"101634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review"],"prefix":"10.1016","volume":"27","author":[{"given":"Lianna","family":"Valdes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob T.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-7590","authenticated-orcid":false,"given":"Janine","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Susarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Papaliodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sobrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2022.101634_bib1","series-title":"Infliximab [package Insert]","year":"2013"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101634_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ajoc.2022.101634_bib3","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101634_bib4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ajoc.2022.101634_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the CORRONA registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ajoc.2022.101634_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-013-2364-6","article-title":"Immunogenicity, the elephant in the room. comment on \u201cdrug levels, anti-drug antibodies and clinical efficacy of the anti-tnf\u03b1 biologics in rheumatic diseases","volume":"32","author":"Pixley","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101634_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179308","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101634_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis","volume":"48","author":"Quistrebert","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101634_bib9","article-title":"The Standardization of Uveitis Nomenclature (SUN) Project. Development of a clinical evidence base utilizing informatics tools and techniques","volume":"52","author":"Trusko","year":"2013","journal-title":"Methods Inf Med"},{"issue":"12","key":"10.1016\/j.ajoc.2022.101634_bib10","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","article-title":"Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies","volume":"123","author":"Cordero-Coma","year":"2016","journal-title":"Ophthalmol Times"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101634_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajoc.2022.101634_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardizatlon of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmol Times"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101634_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","article-title":"Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD","volume":"21","author":"Zitomersky","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.ajoc.2022.101634_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajoc.2022.101634_bib15","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far","volume":"57","author":"Jani","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101634_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of dmards in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2013","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.ajoc.2022.101634_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.ajoc.2022.101634_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014581","article-title":"Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis","volume":"7","author":"Freeman","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ajoc.2022.101634_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3899\/jrheum.160072","article-title":"Prevalence of anti-infliximab antibodies and their associated Co-factors in children with refractory arthritis and\/or uveitis: a retrospective longitudinal cohort study","volume":"44","author":"Aeschlimann","year":"2017","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101634_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ajoc.2022.101634_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ibd.22910","article-title":"Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease","volume":"18","author":"Steenholdt","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.ajoc.2022.101634_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/S0149-2918(02)80075-3","article-title":"Immunogenicity of therapeutic proteins: clinical implications and future prospects","volume":"24","author":"Schellekens","year":"2002","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.ajoc.2022.101634_bib23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622003802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993622003802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:04:21Z","timestamp":1762527861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993622003802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":23,"alternative-id":["S2451993622003802"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101634","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2022.101634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101634"}}